Patients with localized prostate cancer characterized by high-risk features are at increased risk of a negative outcome following radical prostatectomy.
A literature search of new studies clarifies, refutes, and expands on previous recommendations for managing new and established CIPN in patients treated with cytotoxic agents.
Researchers examined causes of avoidable chemotherapy delays as a means of improving the quality of care for outpatients receiving chemotherapy.
Two approaches to downstaging muscle-invasive bladder cancer prior to radical cystectomy include neoadjuvant chemotherapy and transurethral resection.
Findings from a large study of bladder-sparing treatments for muscle-invasive bladder cancer support the routine use of 5-fluorouracil and mitomycin C concomitantly with radiation therapy.
In a phase 2 trial, more than half of patients who received neoadjuvant chemotherapy for high-risk upper tract urothelial carcinoma had a pathologic response that was associated with improved survival.
In a study, nearly 1 in 10 cancer patients on systemic therapy experienced an episode of acute kidney injury.
Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment.
Study findings suggest that clinicians should use neoadjuvant chemotherapy in many more muscle-invasive bladder cancer patients.
One-year overall survival of 61% for gemcitabine and cisplatin plus ipilimumab.
